The energetic and allosteric landscape for KRAS inhibition
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Thousands of proteins have been validated genetically as therapeutic targets for human diseases 1 . However, very few have been successfully targeted, and many are considered ‘undruggable’. This is particularly true for proteins that function via protein–protein interactions—direct inhibition of binding interfaces is difficult and requires the identification of allosteric sites. However, most proteins have no known allosteric sites, and a comprehensive allosteric map does not exist for any protein. Here we address this shortcoming by charting multiple global atlases of inhibitory allosteric communication in KRAS. We quantified the effects of more than 26,000 mutations on the folding of KRAS and its binding to six interaction partners. Genetic interactions in double mutants enabled us to perform biophysical measurements at scale, inferring more than 22,000 causal free energy changes. These energy landscapes quantify how mutations tune the binding specificity of a signalling protein and map the inhibitory allosteric sites for an important therapeutic target. Allosteric propagation is particularly effective across the central β-sheet of KRAS, and multiple surface pockets are genetically validated as allosterically active, including a distal pocket in the C-terminal lobe of the protein. Allosteric mutations typically inhibit binding to all tested effectors, but they can also change the binding specificity, revealing the regulatory, evolutionary and therapeutic potential to tune pathway activation. Using the approach described here, it should be possible to rapidly and comprehensively identify allosteric target sites in many proteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · cited 1×
“Pocket 2 (also called the switch-II pocket) is located between switch-II and α-helix 3 and is the binding site of sotorasib and other clinically approved allosteric inhibitors of KRAS(G12C) 26 .”
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Discovery of a Covalent Inhibitor of KRAS G12C (AMG 510) for the Treatment of Solid Tumors
Lanman, B. A., Allen, J. R., Allen, J. G., Amegadzie, A. K., Ashton, K. S., Booker, S. K., Chen, J. J., Chen, N., Frohn, M. J., Goodman, G., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01180 · Cited by 765 · cited 2×
“Sotorasib is an allosteric inhibitor that binds outside of the nucleotide and effector binding sites to lock KRAS(G12C) in inactive GDP-bound states, reducing effector binding and clinically validating the efficacy of allosteric KRAS inhibition 8,10 .”
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Ostrem, J. M. L., & Shokat, K. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.139 · Cited by 641 · cited 2×
“Pocket 1 (also called the switch-I/II pocket) is located behind switch-II between the central β-sheet and α-helix 2 and is the binding site for multiple inhibitors that are effective in pre-clinical models 24,25 .”
Drugging an undruggable pocket on KRAS
Kessler, D., Gmachl, M., Mantoulidis, A., Martin, L. J., Zoephel, A., Mayer, M., Gollner, A., Covini, D., Fischer, S., Gerstberger, T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904529116 · Cited by 449
Ras Conformational Ensembles, Allostery, and Signaling
Lu, S., Jang, H., Muratcioglu, S., Gursoy, A., Keskin, O., Nussinov, R., & Zhang, J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00542 · Cited by 355 · cited 1×
“An initial single round of nicking mutagenesis using equimolar mixes of degenerate KRAS primers (Supplementary Table 3) was obtained for two reasons: (1) To obtain random single mutants to use as template for another round of nicking mutagenesis (by randomly selecting single colonies and verified by Sanger sequencing)…”
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M., & Kraut, N. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1331 · Cited by 336
The origins and genetic interactions of KRAS mutations are allele- and tissue-specific
Cook, J. H., Melloni, G. E. M., Gulhan, D. C., Park, P. J., & Haigis, K. M. (2021) · Nature Communications · doi:10.1038/s41467-021-22125-z · Cited by 208 · cited 1×
“An initial single round of nicking mutagenesis using equimolar mixes of degenerate KRAS primers (Supplementary Table 3) was obtained for two reasons: (1) To obtain random single mutants to use as template for another round of nicking mutagenesis (by randomly selecting single colonies and verified by Sanger sequencing)…”
Deconstruction of the Ras switching cycle through saturation mutagenesis
Bandaru, P., Shah, N. H., Bhattacharyya, M., Barton, J. P., Kondo, Y., Cofsky, J. C., Gee, C. L., Chakraborty, A. K., Kortemme, T., Ranganathan, R., et al. (2017) · eLife · doi:10.7554/elife.27810 · Cited by 117 · cited 2×
“1a) to previous data that used a different binding assay in a different cellular context 18,19 (Pearson’s r = 0.82; Extended Data Fig.”
Influential
Cited by
Accurate proteome-wide missense variant effect prediction with AlphaMissense
Cheng, J., Novati, G., Pan, J., Bycroft, C., Žemgulytė, A., Applebaum, T., Pritzel, A., Wong, L. H., Zielinski, M., Sargeant, T., et al. (2023) · Science · doi:10.1126/science.adg7492 · Cited by 2,163
(2023) · doi:10.1101/2023.12.07.570727 · Cited by 207
Site-saturation mutagenesis of 500 human protein domains
Beltran, A., Jiang, X., Shen, Y., & Lehner, B. (2025) · Nature · doi:10.1038/s41586-024-08370-4 · Cited by 126
Self-citationMolecular basis of proton sensing by G protein-coupled receptors
Howard, M. K., Hoppe, N., Huang, X.-P., Mitrovic, D., Billesbølle, C. B., Macdonald, C. B., Mehrotra, E., Rockefeller Grimes, P., Trinidad, D. D., Delemotte, L., et al. (2025) · Cell · doi:10.1016/j.cell.2024.11.036 · Cited by 77
Livesey, B. J., & Marsh, J. A. (2025) · Genome Biology · doi:10.1186/s13059-025-03575-w · Cited by 50
Metadata
- Authors
- Weng, C., Faure, A. J., Escobedo, A., & Lehner, B.
- Venue
- Nature
- Published
- 2023-12-18
- Volume
- 626
- Issue
- 7999
- Pages
- 643-652
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W4389916165
- Cited by
- 155
- References
- 10
- FWCI
- 11.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The energetic and allosteric landscape for KRAS inhibition. https://app.cochat.ai/papers/10.1038/s41586-023-06954-0
- The paper
- Weng, C., Faure, A. J., Escobedo, A., & Lehner, B. (2024). The energetic and allosteric landscape for KRAS inhibition. Nature. https://doi.org/10.1038/s41586-023-06954-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.